These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 28548087)
1. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Goodwin J; Neugent ML; Lee SY; Choe JH; Choi H; Jenkins DMR; Ruthenborg RJ; Robinson MW; Jeong JY; Wake M; Abe H; Takeda N; Endo H; Inoue M; Xuan Z; Yoo H; Chen M; Ahn JM; Minna JD; Helke KL; Singh PK; Shackelford DB; Kim JW Nat Commun; 2017 May; 8():15503. PubMed ID: 28548087 [TBL] [Abstract][Full Text] [Related]
2. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma. Schuurbiers OC; Meijer TW; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; van der Drift MA; van der Heijden EH; Oyen WJ; Visser EP; Span PN; Bussink J J Thorac Oncol; 2014 Oct; 9(10):1485-93. PubMed ID: 25170642 [TBL] [Abstract][Full Text] [Related]
3. Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer. Furukawa T; Miyata Y; Kushitani K; Mimae T; Tsutani Y; Takeshima Y; Okada M Jpn J Clin Oncol; 2015 Dec; 45(12):1154-61. PubMed ID: 26386467 [TBL] [Abstract][Full Text] [Related]
4. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters. Koh YW; Lee SJ; Park SY Lung Cancer; 2017 Feb; 104():31-37. PubMed ID: 28212997 [TBL] [Abstract][Full Text] [Related]
5. Zhang W; Bouchard G; Yu A; Shafiq M; Jamali M; Shrager JB; Ayers K; Bakr S; Gentles AJ; Diehn M; Quon A; West RB; Nair V; van de Rijn M; Napel S; Plevritis SK Cancer Res; 2018 Jul; 78(13):3445-3457. PubMed ID: 29760045 [TBL] [Abstract][Full Text] [Related]
6. Associations Between PET Textural Features and GLUT1 Expression, and the Prognostic Significance of Textural Features in Lung Adenocarcinoma. Koh YW; Park SY; Hyun SH; Lee SJ Anticancer Res; 2018 Feb; 38(2):1067-1071. PubMed ID: 29374742 [TBL] [Abstract][Full Text] [Related]
7. Intra-tumoural heterogeneity characterization through texture and colour analysis for differentiation of non-small cell lung carcinoma subtypes. Ma Y; Feng W; Wu Z; Liu M; Zhang F; Liang Z; Cui C; Huang J; Li X; Guo X Phys Med Biol; 2018 Aug; 63(16):165018. PubMed ID: 30051884 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer. Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416 [TBL] [Abstract][Full Text] [Related]
9. Histological subtypes of lung adenocarcinoma have differential ¹⁸F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan. Chiu CH; Yeh YC; Lin KH; Wu YC; Lee YC; Chou TY; Tsai CM J Thorac Oncol; 2011 Oct; 6(10):1697-703. PubMed ID: 21869716 [TBL] [Abstract][Full Text] [Related]
10. [Correlation between SUV of (18)F-FDG PET-CT and the expression of GLUT1, MVD and Ki67 in non-small cell lung cancer]. Duan Y; Yu LJ; Lu PO; Wang WZ Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):764-7. PubMed ID: 19173807 [TBL] [Abstract][Full Text] [Related]
11. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Meijer TW; Schuurbiers OC; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; Verhagen AF; Lok J; van der Heijden HF; Rademakers SE; Span PN; Bussink J Lung Cancer; 2012 Jun; 76(3):316-23. PubMed ID: 22153830 [TBL] [Abstract][Full Text] [Related]
12. The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients. Kim SJ; Hwang SH; Kim IJ; Lee MK; Lee CH; Lee SY; Lee EY J Exp Clin Cancer Res; 2010 Jun; 29(1):69. PubMed ID: 20540786 [TBL] [Abstract][Full Text] [Related]
13. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662 [TBL] [Abstract][Full Text] [Related]
14. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer. Feng A; Tu Z; Yin B Oncotarget; 2016 Apr; 7(15):20507-19. PubMed ID: 26840258 [TBL] [Abstract][Full Text] [Related]
15. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma. Matsuda Y; Yamamoto T; Kudo M; Kawahara K; Kawamoto M; Nakajima Y; Koizumi K; Nakazawa N; Ishiwata T; Naito Z Int J Oncol; 2008 Dec; 33(6):1177-85. PubMed ID: 19020750 [TBL] [Abstract][Full Text] [Related]
16. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298 [TBL] [Abstract][Full Text] [Related]
17. Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168 [TBL] [Abstract][Full Text] [Related]
18. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378 [TBL] [Abstract][Full Text] [Related]
19. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Suzawa N; Ito M; Qiao S; Uchida K; Takao M; Yamada T; Takeda K; Murashima S Lung Cancer; 2011 May; 72(2):191-8. PubMed ID: 20884076 [TBL] [Abstract][Full Text] [Related]
20. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]